FDA censures lax IRB
A company that serves as an independent review board for clinical trials and was the center of a recent Congressional "sting operation" was linkurl:reprimanded;http://www.fda.gov/bbs/topics/news/2009/NEW01996.html today (April 14) by the US Food and Drug Association (FDA) for violating rules protecting research subjects. The company has agreed to freeze some of its key operations. Specifically, under pressure from the FDA, the company, Coast IRB, voluntarily agreed not to approve any new stu
Written byAlla Katsnelson
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
**__Related stories:__***linkurl:Trial safety lacking, says GAO;http://www.the-scientist.com/blog/display/55546/
[ 26th March 2009]*linkurl:Subject death halts clinical trial;http://www.the-scientist.com/blog/display/54825/
[8th July 2008]*linkurl:Paying for patients;http://www.the-scientist.com/article/display/54196/
[February 2008]
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Meet the Author
This person does not yet have a bio.View Full Profile
Share
